The Current Ratio as of November 2024 (TTM) for Exscientia plc (EXAI) is 5.93

According to Exscientia plc’s latest financial reports and current stock price. The company's current Current Ratio is 5.93. This represents a change of -5.60% compared to the average of 6.28 of the last 4 quarters.

Exscientia plc (EXAI) Historical Current Ratio (quarterly & annually)

How has EXAI Current Ratio performed in the past?

The mean historical Current Ratio of Exscientia plc over the last ten years is 6.41. The current 5.93 Current Ratio has changed 9.15% with respect to the historical average. Over the past ten years (40 quarters), EXAI's Current Ratio was at its highest in in the December 2021 quarter at 12.72. The Current Ratio was at its lowest in in the March 2019 quarter at 2.35.

Exscientia plc (EXAI) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Exscientia plc Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Exscientia plc (EXAI) Average Current Ratio

How has EXAI Current Ratio performed in the past?

The current Current Ratio of Exscientia plc (EXAI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Exscientia plc (EXAI) Current Ratio vs. Peers

How is EXAI’s Current Ratio compared to its peers?

Exscientia plc’s Current Ratio is less than VectivBio Holding AG (9.14), less than Zura Bio Limited (12.57), less than Elevation Oncology, Inc. (41.10), less than Icosavax, Inc. (18.06), less than Recursion Pharmaceuticals, Inc. (6.07), less than Atea Pharmaceuticals, Inc. (19.02), greater than Unity Biotechnology, Inc. (4.07), greater than Adaptimmune Therapeutics plc (3.09), less than Mereo BioPharma Group plc (6.07), greater than Pieris Pharmaceuticals, Inc. (3.95), greater than PDS Biotechnology Corporation (3.84), greater than Leap Therapeutics, Inc. (5.10), less than Theseus Pharmaceuticals, Inc. (29.93), less than aTyr Pharma, Inc. (6.07), less than Relay Therapeutics, Inc. (15.64), less than Century Therapeutics, Inc. (10.62), greater than Blueprint Medicines Corporation (3.32), less than Revolution Medicines, Inc. (15.42), greater than Sana Biotechnology, Inc. (5.20), less than Kymera Therapeutics, Inc. (8.55), less than Monte Rosa Therapeutics, Inc. (6.56),

Build a custom stock screener for Exscientia plc (EXAI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exscientia plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Exscientia plc (EXAI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Exscientia plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.